C
EDIT icon

Covestor’s Editas Medicine EDIT Stock Holding History

Covestor’s Portfolio EDIT Stock Details EDIT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$0 Buy
108
+45
+71% +$132 ﹤0.01% 2556
2026
Q1 		$0 Hold
63
– – ﹤0.01% 2374
2025
Q4 		$0 Sell
63
-1
-2% -$3 ﹤0.01% 2361
2025
Q3 		$0 Hold
64
– – ﹤0.01% 2384
2025
Q2 		$0 Sell
64
-4
-6% -$7 ﹤0.01% 2324
2025
Q1 		$0 Buy
68
+40
+143% +$59 ﹤0.01% 2339
2024
Q4 		$0 Buy
28
+19
+211% +$48 ﹤0.01% 2342
2024
Q3 		$0 Sell
9
-1
-10% -$4 ﹤0.01% 2331
2024
Q2 		$0 Hold
10
– – ﹤0.01% 2342
2024
Q1 		$0 Sell
10
-1
-9% -$8 ﹤0.01% 2342
2023
Q4 		$0 Sell
11
-1
-8% -$9 ﹤0.01% 2255
2023
Q3 		$0 Sell
12
-2
-14% -$17 ﹤0.01% 2230
2023
Q2 		$0 Hold
14
– – ﹤0.01% 2241
2023
Q1 		$0 Sell
14
-1,450
-99% -$12.9K ﹤0.01% 2145
2022
Q4 		$13K Sell
1,464
-1
-0.1% -$11 0.01% 1192
2022
Q3 		$18K Sell
1,465
-1
-0.1% -$16 0.02% 1023
2022
Q2 		$17K Sell
1,466
-3
-0.2% -$40 0.01% 1016
2022
Q1 		$28K Buy
1,469
+1,454
+9,693% +$27K 0.02% 962
2021
Q4 		$0 Buy
+15
New +$516 ﹤0.01% 2163

Other funds holding EDIT

TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
ACM
ADAR1 Capital Management Austin, Texas $2.19B AUM 374.99% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
PBA
Paradigm Biocapital Advisors New York $5.34B AUM 380.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $1.1B AUM 197.64% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Covestor's EDIT Position: Q2 2026 in Review

Covestor increased its Editas Medicine (EDIT) stake by 71% in Q2 2026, buying an estimated $132 and bringing the position to 108 shares worth $0. The position accounts for ﹤0.01% of the portfolio, ranked #2556.

Covestor first reported a position in EDIT in Q4 2021 and has held it in 19 quarters since. The position peaked at $28K in Q1 2022. 215 funds tracked by Wall St. Rank hold EDIT as of Q2 2026.

  • Covestor held 108 shares of Editas Medicine worth $0 as of Q2 2026.
  • Covestor bought 45 Editas Medicine shares in Q2 2026, an estimated $132.
  • Editas Medicine made up ﹤0.01% of Covestor's portfolio in Q2 2026, its #2556 holding.
  • Covestor first reported a position in Editas Medicine in Q4 2021 and has held it in 19 quarters since.
  • Covestor's Editas Medicine position peaked at $28K in Q1 2022.
  • 215 funds tracked by Wall St. Rank held Editas Medicine as of Q2 2026.

Based on Covestor's 13F filing for Q2 2026, filed 7 Aug 2026.